Abstract
Background
Anti-TNF therapies have revolutionized the treatment of autoimmune inflammatory conditions. Paradoxical treatment with these agents is associated with the development of de novo autoimmune diseases. Less well recognized is the provocation of de novo IBD by these agents. Etanercept is not effective for the treatment of inflammatory bowel disease and may be more often reported with the development of Crohn’s disease or ulcerative colitis.
Aim
This study assessed the association of new onset IBD in patients with receiving etanercept.
Methods
The Brigham and Women’s (BWH) patient database and the FDA Adverse Event Reporting System were searched for cases of IBD reported with etanercept.
Results
A total of 443 cases were identified: 5 pts at BWH (3 CD, 2 UC) and 438 (294 CD, 144 UC) reported to the FDA. Data which were most complete were pooled from 49 patients. NSAID use was reported in 43 % and combination with methotrexate in 29 %. Etanercept was discontinued in 34 pts and 19 required treatment with a different anti-TNF agent. Eight patients had resolution of GI symptoms on discontinuation of etanercept. Therapy was continued in three patients in response to 5-ASA therapy.
Conclusion
Development of IBD should be suspected in patients receiving etanercept who develop GI symptoms. This phenomenon appears more commonly associated with initiation of CD. The clinical phenotype appears indistinguishable from usual patterns of IBD. Unlike other autoimmune phenomenon associated with anti-TNF therapy, IBD often does not resolve when the agent is discontinued. This tentative association requires further investigation.
Abbreviations
- IBD:
-
Inflammatory bowel disease
- FDA:
-
Food and Drug Administration
- CD:
-
Crohn’s disease
- UC:
-
Ulcerative colitis
- TNF:
-
Tumor necrosis factor
- BWH:
-
Brigham and Women’s Hospital
- RPDR:
-
Research Patient Database Registry
- FAERS:
-
Food and Drug Administration Adverse Event Reporting System
References
Vermeire S, Noman M, Van Assche G, et al. Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn’s disease: a prospective cohort study. Gastroenterology. 2003;125:32–39.
Subramanian S, Yajnik V, Sands BE, et al. Characterization of patients with infliximab-induced lupus erythematosus and outcomes after retreatment with a second anti-TNF agent. Inflamm Bowel Dis. 2011;17:99–104.
Fouache D, Goeb V, Massy-Guillemant N, et al. Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: a retrospective study. Rheumatology (Oxford). 2009;48:761–764.
Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn’s disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2001;121:1088–1094.
Toussirot E, Houvenagel E, Goeb V, et al. Development of inflammatory bowel disease during anti-TNF-alpha therapy for inflammatory rheumatic disease: a nationwide series. Joint Bone Spine. 2012;79:457–463.
Murphy SN, Chueh HC. A security architecture for query tools used to access large biomedical databases. In: Proceedings AMIA Symposium 2002:552–556.
FDA. The Adverse Event Reporting System (AERS) U.S. Food and Drug Administration. Volume 2014.
Quartier P, Taupin P, Bourdeaut F, et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum. 2003;48:1093–1101.
Van den Brande JM, Braat H, van den Brink GR, et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn’s disease. Gastroenterology. 2003;124:1774–1785.
Marotte H, Cimaz R. Etanercept—TNF receptor and IgG1 Fc fusion protein: is it different from other TNF blockers? Expert Opin Biol Ther. 2014;14:569–572.
Tichy M, Hercogova J. Manifestation of Crohn’s disease in a young woman during the course of treatment for severe form of chronic plaque psoriasis with etanercept. Dermatol Ther. 2014;27:211–214. doi:10.1111/dth.12119.
Wiegering V, Morbach H, Dick A, et al. Crohn’s disease during etanercept therapy in juvenile idiopathic arthritis: a case report and review of the literature. Rheumatol Int. 2010;30:801–804.
Jethwa H, Mann S. Crohn’s disease unmasked following etanercept treatment for ankylosing spondylitis. BMJ Case Rep. 2013. doi:10.1136/bcr-2013-009166.
Krishnan A, Stobaugh DJ, Deepak P. Assessing the likelihood of new-onset inflammatory bowel disease following tumor necrosis factor-alpha inhibitor therapy for rheumatoid arthritis and juvenile rheumatoid arthritis. Rheumatol Int. 2015;35:661–668. doi:10.1007/s00296-014-3133-9.
Cohen R, Robinson D Jr, Paramore C, et al. Autoimmune disease concomitance among inflammatory bowel disease patients in the United States, 2001–2002. Inflamm Bowel Dis. 2008;14:738–743.
Rudwaleit M, Baeten D. Ankylosing spondylitis and bowel disease. Best Pract Res Clin Rheumatol. 2006;20:451–471.
Haraoui B, Krelenbaum M. Emergence of Crohn’s disease during treatment with the anti-tumor necrosis factor agent etanercept for ankylosing spondylitis: possible mechanisms of action. Semin Arthritis Rheum. 2009;39:176–181.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors have no financial disclosures.
Rights and permissions
About this article
Cite this article
O’Toole, A., Lucci, M. & Korzenik, J. Inflammatory Bowel Disease Provoked by Etanercept: Report of 443 Possible Cases Combined from an IBD Referral Center and the FDA. Dig Dis Sci 61, 1772–1774 (2016). https://doi.org/10.1007/s10620-015-4007-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-015-4007-z